SHANK3 and epilepsy: To date, pharmacological treatments for ASDs and other developmental disorders (including SHANK3-haploinsufficiency syndromes) are primarily ameliorative, focusing on managing associated systems such as anxiety, aggression, repetitive behaviors, attention deficits and epilepsy, among others (see, for example, [60]).